J. Safra Sarasin Holding AG Raises Stock Holdings in DaVita Inc. $DVA

J. Safra Sarasin Holding AG lifted its holdings in shares of DaVita Inc. (NYSE:DVA) by 332.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,597 shares of the company’s stock after acquiring an additional 7,376 shares during the period. J. Safra Sarasin Holding AG’s holdings in DaVita were worth $1,275,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hantz Financial Services Inc. grew its position in DaVita by 48.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of DaVita during the second quarter worth about $36,000. Canada Pension Plan Investment Board purchased a new position in shares of DaVita during the second quarter worth about $43,000. Ameritas Advisory Services LLC acquired a new position in DaVita in the 2nd quarter valued at about $47,000. Finally, Employees Retirement System of Texas purchased a new stake in DaVita during the 2nd quarter valued at approximately $49,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

DVA has been the topic of several analyst reports. Barclays lowered their target price on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 30th. Wall Street Zen lowered shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. TD Cowen restated a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. Truist Financial cut their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research note on Monday, January 5th. Finally, UBS Group reissued a “buy” rating on shares of DaVita in a research note on Monday, December 15th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $145.60.

DaVita Trading Up 0.2%

Shares of DaVita stock opened at $105.86 on Thursday. The business’s fifty day moving average price is $113.97 and its 200 day moving average price is $125.67. The stock has a market capitalization of $7.47 billion, a P/E ratio of 10.90, a PEG ratio of 0.65 and a beta of 0.99. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The company’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm earned $2.59 earnings per share. As a group, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.